Wendy's Rejects Trian Partners Acquisition Bid, Adopts Poison Pill
Key Facts
The Wendy's Company independent committee unanimously rejected a $7.35 per share cash acquisition proposal from a group led by Trian Partners. According to a statement on PR Newswire, the board determined that the unsolicited bid significantly undervalues the company's upside potential from its newly announced 'Dave's Way' strategic plan.
The company adopted a limited-duration shareholder rights plan, or poison pill, to protect its strategic interests and prevent hostile takeovers. WEN closed at $7.65 on November 4, 2026, trading above the offer price proposed by the investor group, which includes Flynn Group LP, BlueFive Capital, and Sixth Street Partners.
Latest Updates · 3
- Notable·
Update: The takeover offer from Trian Partners was valued at approximately $1.4 billion. This total valuation is based on the $7.35 per share cash bid that the Wendy's independent committee rejected.
- Notable·
Update: The total value of the cash acquisition proposal from the group led by Trian Partners was approximately $1.4 billion. This valuation comes as Wendy's maintains its focus on its independent strategic growth objectives.
- Notable·
Update: Wendy's reported its Q3 2026 financial results on November 5, 2026, generating $547.0 million in revenue and $15.1 million in net income. The company also signed a letter-of-intent to acquire up to 163 restaurants from Meritage Hospitality Group to optimize its portfolio.